Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4661 Comparison of preoperative chemotherapy and radio ligand therapy on prognosis after surgical resection for locally advanced or hepatic metastatic pancreatic neuroendocrine tumours

Introduction: The role of preoperative treatments in improving the rate of radical resection and survival of either locally advanced (LA) or hepatic metastatic (HM) pancreatic neuroendocrine tumours (panNETs) is unclear.

Conference:

Presenting Author:

Authors: Provinciali L, de Mestier L, Pontillo D, Guarneri G, Partelli S,

Keywords: adjuvant therapy, chemotherapy, event free survival, liver transplantation, RadioLigand Therapy,

#4567 Malignant pheochromocytoma with late distant metastases and secondary hypercalcaemia

Introduction: Pheochromocytoma is a rare neuroendocrine tumour of the adrenal medulla. Malignant variants occur with a very low frequency and can be diagnosed only after the spread of distant metastasis.

Conference:

Presenting Author:

Authors: Kirova I, Vandeva S, Markova M, Elenkova A, Robeva R,

Keywords: neuroendocrine, malignant pheochromocytoma, metastasis, hypercalcaemia,

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4049 A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)

Introduction: Surgery is the primary treatment and only possible cure for pNET. Unresectable pNET necessitates conversion therapy to obtain opportunity of radical resection. Former trials have shown potential of Surufatinib (S) and CAPTEM as conversion therapy in pNET.

Conference:

Presenting Author: Wang Z

Authors: Wang Z, Cao D, Ke N,

Keywords: pNET, Conversion therapy, Surufatinib, CAPTEM,

#3941 Association of body composition with survival in patients with Pancreatic Neuroendocrine Tumors (PNET) following curative resection

Introduction: The body composition has been demonstrated to be associated with the prognosis of various cancers. However, the prognostic value of body composition in patients with pancreatic neuroendocrine tumors (pNETs) following curative resection is still unknown.

Conference:

Presenting Author: Xie Z

Authors: Shen X, Wang Z, Liu X, Wang X, Xie Z,

Keywords: body composition, pNETs, computed tomography, survival,